The extracellular matrix in the lung must be destroyed for Mycobacterium tuberculosis-the agent that causes tuberculosis (TB)-to spread. The current paradigm proposes that this destruction occurs as a result of the action of pro-inflammatory cytokines, chemokines, immune cells, and lipids that mediate TB-associated necrosis in the lung. However, this view neglects the fact that lung matrix can only be degraded by proteases. We propose an original conceptual framework of TB immunopathology that may lead directly to treatments that involve inhibition of matrix metalloproteinase activity to hinder matrix destruction and thereby reduce the morbidity and mortality associated with TB.
INTRODUCTION
Tuberculosis, an infectious disease caused by Mycobacterium tuberculosis (Mtb), affects about one third of the world's population (1). Although most infections are asymptomatic, active tuberculosis, usually primarily involving the lungs, is often fatal . Despite the intensive biomedical research efforts of the last two decades, the standard TB treatment regime has remained unchanged for over 30 years. Although it is widely accepted that immunopathology-that is, an excessive host immune response to mycobacterial antigenscauses mortality in patients (2) , and also drives the destruction of the extracellular matrix that is necessary for the spread of M. tuberculosis (Mtb), understanding of this process remains surprisingly vague (3) . A contributing factor is the imprecise terminology used to describe TB-related tissue damage, such as "immunopathology," "delayed-type hypersensitivity" (a secondary, cell-mediated immune reaction that occurs several days after antigen exposure), and "caseous necrosis" (the accumulation of amorphous debris characteristic of TB infection). Patients die from this TB-associated immunopathology, which often worsens during initial treatment and so mortality continues even after starting effective antituberculous agents. Fear of driving pathology also prevents the development of immunostimulatory strategies to reduce treatment duration from the current minimum of 6 months. Therefore, we need a better understanding of the mechanisms of TB-related pathology to reduce deaths from TB and to introduce short course treatment regimes.
HISTORIC TERMINOLOGY OF TB PATHOLOGY
TB is primarily a disease of the lung, which has an intricate structure of air-filled alveoli to permit gas exchange. Mtb is phagocytosed by macrophages, the central effector cells of the innate immune response. The microscopic pathology caused by Mtb in humans has been described as caseous necrosis for over 100 years, because of the accumulation of material with a cheese-like appearance in the center of TB-associated granulomas (cell aggregates-in which lymphocytes surround infected macrophages-that are thought to form to isolate Mtb). Lung infection leads to cavitation, which is the development of large airfilled spaces within the lung where the intricate parenchymal structure has been completely destroyed (Fig. 1) . Mtb then proliferates exponentially in the cavity, essentially walled off from the host immune response (4), and each cavity may contain up to 10 9 mycobacteria (5).
The current paradigm of TB pathology states that accumulating caseous material erodes into an airway, creating a cavity within which the Mtb proliferates freely (Fig. 2 , black arrows).
This paradigm was developed from the rabbit model during seminal work in the 1960s by Lurie and Dannenberg, and they highlighted the likely involvement of proteases, lipases and nucleases (6) . However, in current TB reviews the involvement of proteases is completely All of these models overlook the fact that cavity formation must involve destruction of the lung extracellular matrix, which includes a complex, highly stable network of collagen fibrils (15) that supports the structure of the lung and that, when intact, regulates many aspects of inflammation (16) . Matrix breakdown has historically been considered part of a single process of caseous necrosis (8) , but the death of cells to cause caseation is likely to be a distinct process from extracellular matrix destruction (Fig. 2 , red arrows). Indeed, the network of collagen fibrils can only be degraded by proteases. The cytokines, chemokines, T cells, and lipids that have been proposed as the mediators of caseous necrosis simply cannot degrade fibrillar collagens, the primary structural fibrils of the lung (15) . The inescapable conclusion is that matrix destruction that leads to lung cavitation in TB must result from protease activity.
LUNG MATRIX BIOCHEMISTRY PREDICTS A CENTRAL ROLE FOR METALLOPROTEASES
The human lung has evolved to be highly resistant to destruction of the extracellular matrix; for example, even after exposure to cigarette smoke for a lifetime, the majority of 
THE URGENT CLINICAL NEED TO LIMIT IMMUNOPATHOLOGY
TB continues to kill almost 2 million people per year (1) and these patients die from TB-related tissue destruction. Furthermore, the introduction of new anti-tuberculous drugs with rapid bactericidal activity, such as TMC207 (32), will increase the early release of Mtb antigen and consequently drive pathology. Ironically, very rapid killing of the pathogen may also kill the host if the mycobacterial load is high. Similarly, the early introduction of antiretroviral therapy for patients with TB-HIV co-infection, which reduces mortality, will increase incidence of TB immune reconstitution inflammatory syndrome, which is characterised by tissue destruction (30) . (This condition occurs when the immune system begins to recover and responds to Mtb infection, paradoxically causing worsening pathology New approaches to limit TB-related immunopathology, both in cavitatory and disseminated TB, are needed to reduce mortality and to permit immunostimulatory approaches to shorten treatment. If one breaks down TB pathology into its constitutive parts, MMPs emerge as the immunopathological mediators most readily targeted with orally available compounds.
MMP INHIBITION TO REDUCE IMMUNOPATHOLOGY IN TB
If MMPs are proven to be the final common effectors of matrix destruction in TB, MMP inhibition emerges as an attractive strategy to limit TB morbidity and mortality. Many MMP inhibitors were developed in the 1990's as they showed initial promise in the treatment of cancer (33) . Although results of the first trials in that clinical context were disappointing, in part because of musculoskeletal side-effects, more selective inhibitors are now available.
In addition, MMP inhibition in TB would be of relatively short duration. Tetracycline antibiotics are broad spectrum MMP inhibitors, acting both at a pre-transcriptional level and also directly as enzyme inhibitors (34) . Doxycycline (a type of tetracycline), prescribed at a sub-antimicrobial dose of 20 mg twice a day, is licensed by the U.S. Food and Drug
Adminstration to limit MMP activity in periodontal disease (35) . Doxycycline is cheap, safe, and widely available, so could be readily deployed in resource poor settings. A more potent, selective collagenase inhibitor, Ro32-3555, has passed phase III clinical trials for patients with arthritis (36) , and so has the potential to prevent lung matrix destruction. Other MMP inhibitors have been developed that would merit study in appropriate animal models of TB (34) . A central question is whether a specific MMP should be targeted or whether broadspectrum MMP inhibition will be more efficacious.
In summary, extracellular matrix destruction is one of the critical pathological events in TB. Defining mechanisms of TB immunopathology identifies MMP activity as a potential therapeutic target to limit morbidity and mortality in TB. 
